1 2	Analysis of opioid distribution before and after recreational marijuana legalization in California
3 4 5	Michelle N. Anyaehie, MBS ¹ , Christian Pardo, MBS ¹ , Elijah J Johnson, MBS ¹ , Chucks Anachebe MBS ¹ , Brian J. Piper, PhD ^{1,2}
6 7 8	¹ Geisinger Commonwealth School of Medicine, Scranton, PA 18590 ² Center for Pharmacy Innovation and Outcomes, Forty Fort, PA
9	525 Pine St, Scranton, PA 18510
10	Correspondence: Michelle N Anyaehie: manyaehie@som.geisinger.edu
11	
12	Word count
13 14 15 16 17	 Abstract: 193 Manuscript: 2,195 Figures: 4 Supplemental Figures: 2 Tables: 0
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	

31 Abstract

The opioid epidemic has risen to an all-time high. Harm reduction and prevention 32 policies have not alleviated this crisis. Recent investigations have highlighted the 33 34 efficacy and safety of marijuana-based products for pain management. Providing alternative pain treatment options may help mitigate the opioid epidemic. The 35 distribution of codeine, fentanyl, hydrocodone, morphine, and oxycodone per 100K 36 people and by 3-digit zip codes and overdose rates from 2014 to 2018 in California. 37 which legalized recreational marijuana in 2016, were compared to Texas, where 38 marijuana is functionally prohibited. Drug weights were obtained from the Automation of 39 Reports and Consolidated Orders System and converted to oral morphine milligram 40 equivalents. Overdose data was retrieved from the Centers for Disease Control's 41 42 WONDER database. California (-43.7%) and Texas (-27.3%) showed significant 43 reductions in cumulative opioid distribution from 2014 to 2018. Opioid distribution per 100K people decreased -38.9% in California relative to -26.4% in Texas. Opioid and 44 45 heroin overdoses increased between 1999 and 2019 by +11.6% in California but 46 +272.7% in Texas. This evidence supports marijuana legalization as a mitigating factor 47 to the opioid epidemic. Continued studies on safer pain management alternatives and 48 policies will help identify measures that help combat the opioid epidemic.

49 50

- 51

Key words: Marijuana, cannabis, opioid epidemic, medical marijuana, opioids, pain
 management

54 Introduction

Under the Controlled Substance Act of 1970, marijuana is classified as a 55 56 schedule I drug along with heroin and ecstasy. Schedule I substances are defined as 57 having high abuse potential and no medical efficacy. Various opioids are listed as schedule II drugs, which have limited medical use with a high abuse potential, and 58 59 certain opioid combination drugs are listed as schedule III (e.g., acetaminophen with codeine). Here, the opioid distributions of fentanyl, oxycodone, morphine, hydrocodone, 60 and codeine, listed in order of decreasing potency (List Of Opioids From Strongest To 61 Weakest - Addiction Resource, 2020), as well as opioid overdose rates in California 62 after legalization of recreational marijuana have been analyzed. California legalized 63 medical marijuana in 1996 and recreational marijuana in 2016. 64

The opioid epidemic is characterized by a steep increase in opioid prescription 65 rates followed by a rise in opioid-related deaths in the early 1990s. Opioid prescriptions 66 guadrupled from 1998 to 2008 and resulted in alarming overdose rates (Jones et al., 67 2018). Nationwide opioid prescription rates steadily increased from 2006 to 2012 but 68 started decreasing from 2013 to 2018 (CDC Injury Center, 2020), showing there has 69 been an effort to alleviate the crisis. Removing pain as the fifth vital sign, implementing 70 drug disposal programs, and returning unused medications are several measures that 71 72 have been enacted (Cabrera et al., 2019). However, these measures have had little to no effect on opioid distribution and control of opioid-related deaths. In fact, there were 73 approximately 65,000 deaths in 2016, an increase of 21% from the year prior (Jones et 74 75 al., 2018). California reported six opioid related deaths per 100K people in 2018 (California: Opioid-Involved Deaths and Related Harms | National Institute on Drug 76

Abuse (NIDA), 2020.). Comparably, Texas reported five opioid related deaths per 100K
people in 2018 (*Texas: Opioid-Involved Deaths and Related Harms* | *National Institute on Drug Abuse (NIDA)*, 2020). The opioid prescription rate was 35.1 prescriptions per
100 persons in California (Huey & Apollonio, 2019) and 47.2 in Texas (*Texas: Opioid- Involved Deaths and Related Harms* | *National Institute on Drug Abuse (NIDA)*, n.d.) in
2018.

Due to stringent federal legislature, there has been little research deciphering the 83 effects of medical marijuana, particularly using products available at dispensaries, and 84 therefore the relationship between marijuana use and trends in opioid distribution and 85 narcotic overdoses has not been fully elucidated. However, California legalized 86 medicinal marijuana in 1996 and recreational marijuana in 2016. Recreational 87 dispensaries opened to individuals who were at least 21 years of age in January 2018. 88 As data demonstrating marijuana's success as an alternative to opioids is presented 89 90 (Blake et al., 2019; Boehnke et al., 2016; Kienzl et al., 2020; Lee et al., 2018; Sagy et al., 2019; Ware et al., 2015)), resulting opioid trends can be analyzed. In this study, 91 opioid distribution rates in California, where medical marijuana and recreational 92 93 marijuana use was legalized, by zip code and per capita, were compared to Texas, which has not legalized recreational or medical marijuana. Texas caps the percent 94 tetrahydrocannabinol at 0.5% and enrollment (3,519 in Dec, 2020) in their program 95 relative to state's population is modest (Sparber & Jones, 2021). We hypothesize that 96 97 there will be a greater decrease in opioid distribution in California following the change in marijuana legislation than in Texas. 98

99 Methods

100 Procedure

The Drug Enforcement Administration's Automation of Reports and Consolidated 101 102 Orders System (ARCOS) Database is used to track controlled substances from manufacture, through distribution channels to point-of sale at the level of hospitals, 103 pharmacies, practitioners, and teaching institutions. The data is organized in several 104 reports summarizing drug distribution by first three-digits of the zip code, per 100K 105 population gathered and includes summaries of purchases. Report 1, which reports 106 drug distribution by zip code, and Report 3, which reports quarterly drug distribution by 107 state per 100.000 population by gram were selected for analysis (ARCOS Retail Drug 108 Summary Report - 2011 Reporting Period, n.d.; Ighodaro et al., 2019). Fentanyl, 109 oxycodone, morphine, hydrocodone and codeine were chosen based on their familiarity 110 in the general population and inclusion in prior research (Cabrerra et al. 2018; Ighodaro 111 et al. 2019; Piper et al. 2017). ARCOS data has been previously validated by comparing 112 results to a state Prescription Drug Monitoring Program which showed a satisfactory (r = 113 0.985) agreement (Piper et al., 2017). 114

The Center for Disease Control WONDER database was constructed to facilitate access to public health information for state and local health departments and the academic public health community (Friede et al., 1994). The mortality data was extracted from WONDER as "Drug-induced causes" set as the underlying cause of death with the Multiple Cause of Death ICD-10 codes T40.1- "Heroin" and T40.2- "Other opioids". ICD-10 code T40.1 is limited to heroin induced deaths. ICD-10 code T40.2 excludes non-opioid narcotics, such as cocaine, opium, and LSD, and may include but

is not limited to codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone,

and tramadol. Total overdose rate includes heroin and other opioid induced deaths.

124 Data Analysis

The weights of five common opioids codeine, fentanyl, hydrocodone, morphine, and oxycodone) were converted to oral Morphine Milligram Equivalents (MME) (Piper et al., 2018). Outliers were tested for using Grubbs' Test on GraphPad Prism. Heat maps and graphs were constructed using Microsoft Excel and GraphPad Prism 8. Two-tailed paired equal variance t-tests were performed using GraphPad Prism 8 software on zip code distribution data to determine statistical differences with p<0.05 considered

131 significant.

132 **Results**

133 **Opioid Distribution by Zip Code**

In both 2014 and 2018, California showed much more widespread and 134 substantial cumulative opioid distribution as seen in Fig. 1(A-B). In 2014, portions of 135 California surrounding the Bay Area and portions of Southern California had cumulative 136 opioid distributions as high as 1,388,000 MME and 900,000 MME, respectively. In 137 contrast, the highest distribution in Texas was 790,000 MME in the surrounding Dallas 138 area. Most of Texas had a distribution of 100,000 or less while most zip codes in 139 California ranged from 150,000 to 650,000 (Fig. 1A). However, in 2018, the largest 140 distributions in California dropped to 720,000 MME in the Bay Area and 525,000 MME 141 in Southern California, decreases of 50 and 40 percent respectively (Fig. 1B). The 142 surrounding Dallas area saw a decrease of 25 percent while most of Texas did not 143 show a comparable decrease (Fig. 1C). Both California (p<0.0001) and Texas 144 (p<0.0001) showed statistically significant decreases in opioid distribution, but California 145

had an over two-fold difference per zip code (162,476 versus 62,808 MME) over this
five-year span. This represents a -43.7% decrease in California relative to only -27.3%
in Texas (Fig. 2). There was an increase of 6,000 MME in a 16-zip code area of
Southern California near Glendale and Burbank. In this area, fentanyl, morphine, and
oxycodone saw 1.5, 2.4, and 1.8-fold increases respectively while codeine and
hydrocodone did not undergo appreciable changes (Fig. 1C).
Opioid Distribution Per Capita
Opioid distribution per capita decreased in both California and Texas from 2014

153 to 2018 (-38.9% and -26.4% respectively). The change in California was more linear for 154 all opioids while Texas experienced more variable change (Fig. 3). Distribution of all five 155 opioids in California decreased to a greater extent than their Texan counterparts 156 157 (hydrocodone -65.4%, fentanyl -50.3%, morphine -42.7%, oxycodone -32.4%, and codeine -19.1%, Fig. 3). Individual opioid distribution changes in Texas showed much 158 more variability with hydrocodone, fentanyl, and morphine distribution decreasing (-159 160 42.3%, -36.7%, and -27.8%), oxycodone remaining essentially unchanged (-0.5%), and 161 codeine distribution increasing 150.1% (Fig. 3).

162 **Overdose rates**

Overall, opioid related deaths increased in California (11.6%) and Texas (272.7%) between 1999 and 2019. California showed a decline in deaths from nonheroin opioids between 2014-2019 (Fig. 4A) while Texas had an increase in deaths from 2014-2017 and then experienced a decline in 2018 (Fig. 4B). Heroin related deaths have increased continuously in California (71.4%) and Texas (400%) between 1999 and 2019.

169 **Discussion**

The observed trends in opioid distribution by zip code and per capita in California 170 171 and Texas support recreational marijuana legalization as a practical measure to help 172 reduce prescription opioid use. The five years analyzed (2014 – 2018) show a greater decrease in California than in Texas (Fig. 2). Opioid distribution per 100K people in 173 174 California decreased 38.9% from 2014-2018 while distribution in Texas decreased by only 26.4% (Fig. 3). Similarly, heat map analysis (Fig. 1(A-B) illustrates a greater 175 decrease in opioid distribution over large areas of California compared to Texas from 176 2014 to 2018. These findings are consistent with investigations showing fewer opioid 177 prescriptions written in states where medical marijuana laws are passed (Bradford & 178 Bradford, 2016). A similar study showed a significant correlation between increased 179 marijuana use as a treatment for chronic pain and reduced opioid use (Boehnke et al., 180 2016), suggesting a potential public health benefit of replacing opioids with cannabis. 181 The drop in hydrocodone and increase in codeine and oxycodone distribution per 182 capita seen in Texas (Fig. 3) is consistent with previous data showing that oxycodone 183 and codeine increased by weight distribution from 2014 to 2017 specifically in Texas 184 (Texas: Opioid-Involved Deaths and Related Harms | National Institute on Drug Abuse 185 (NIDA), n.d.). The reclassification of hydrocodone in 2014 from a schedule III to a 186 187 schedule II may be a factor behind this trend (Bohnert et al., 2018; Texas: Opioid-Involved Deaths and Related Harms | National Institute on Drug Abuse (NIDA), n.d.). 188 Increased restrictions surrounding hydrocodone may have created an environment for 189 190 the distribution of oxycodone and codeine to rise as there were fewer powerful analgesic options available, such as cannabis products. 191

The decreasing trends observed in California (Fig.3) may be explained by current 192 approaches to treating pain and the reduction in opioid use as a result of medicinal and 193 recreational marijuana legalization. Three-fifths (62%) of women surveyed in California 194 and Colorado with gynecological malignancies stated their interest in non-prescription 195 cannabis and 35.6% were interested in using cannabis under the guidance of 196 197 physicians. One-quarter (26.7%) of these patients reported already using nonprescription cannabis products to manage various cancer related symptoms (Blake et 198 al., 2019). 199

200 California saw a decrease in overdose deaths after the legalization of marijuana in 2016 and 2018 (Fig.4), whereas Texas, which has not legalized marijuana, 201 experienced a rise in deaths by overdose in 2016 and 2017 however a gradual 202 decrease in 2018 was also shown. Results from our data could be accounted for by the 203 implementation of laws across the U.S. designed to mitigate overdoses by limiting 204 205 opioid prescriptions and institutionalizing Prescription Drug Monitoring Programs introduced in 2017 (McGinty et al., 2018). Prior research has found that any association 206 207 between medical marijuana and opioid overdoses is complicated (Bachhuber et al., 208 2014; Kaufman et al., 2021; Shover et al., 2019), but further studies will help describe the raltionship between changing marijuana legislature and opioid overdoses. 209

Although harm reduction policies and medication-assisted treatments for opioid dependence have increased in availability, (e.g. sterile syringe access programs and methadone) (Bohnert et al., 2018), alternative pain management strategies must be employed to decrease access and use of opioids to lower addiction and overdose rates. States that enacted medical cannabis laws had a 24.8% reduction in opioid overdose

mortality which further decreased in the years following their implementation
(Bachhuber et al., 2014). Evidence supports the promotion of safer and less addictive
alternatives for analgesic relief, and implementation of laws that could reduce the
misuse and abuse of opioids.

There were a variety of limitations to our study. Limited research on recreational 219 220 and non-prescription marijuana for analgesic effects makes it difficult to make accurate analysis and inferences. Most findings on cannabis and chronic pain refer to medical 221 cannabis, but patients have reported using recreational and non-prescription cannabis 222 223 for medical benefits (Blake et al., 2019). Surveys taken to assess the use of recreational and non-prescription marijuana from dispensaries would help differentiate between 224 225 recreational and medicinal marijuana use. The data extracted from ARCOS presented a further limitation as the census data used by the Drug Enforcement Administration is 226 from 2010. Including more control states and utilizing 2020 census data, when 227 228 available, might be beneficial in future studies (Andreae et al., 2016). In addition, ARCOS does not account for mail-order pharmacies and internet pharmacies that ship 229 different prescription opioids across state lines, including the five opioids used in this 230 231 study (California: Opioid-Involved Deaths and Related Harms | National Institute on Drug Abuse (NIDA), n.d.). Lastly, statistics gathered from CDC WONDER database do 232 not provide specific details on overdose outcomes and includes overdoses from all 233 opioids, not just the five previously discussed. Overdose data from WONDER may also 234 235 be underestimated and accuracy varies from state to state as there is no standardized national reporting practice (California: Opioid-Involved Deaths and Related Harms | 236 National Institute on Drug Abuse (NIDA), n.d.: Texas: Opioid-Involved Deaths and 237

238 Related Harms | National Institute on Drug Abuse (NIDA), n.d.; Kaufman et al., 2021).

- However, both California and Texas were rated by the CDC as in the same "less than
- good" category for death determination quality (Kaufman et al., 2021).

241 Conclusion

- 242 Prescription opioid distribution in California showed a greater decrease
- compared to Texas (43.7% and 27.3% respectively). These findings suggest a
- relationship between California's marijuana legislation and the decreased opioid
- distribution when compared to a state that has legislation prohibiting medicinal or
- recreational marijuana use. As more states increase access to cannabis, trends in
- opioid distribution and use, as well as opioid overdoses, must be further analyzed to
- 248 promote legislature to help combat the opioid epidemic.

249 Author Contributions


- 250 Michelle N Anyaehie conceived and designed the study, performed literature search
- and review, authored drafts of the paper, analyzed the data and approved the final manuscript.
- 253 Christian Pardo conceived and designed the study, preformed literature search and 254 review, analyzed the data, prepared figures, authored drafts of the paper, and approved 255 the final manuscript.
- Elijah J Johnson conceived and designed the study, preformed literature search and review, authored drafts of the paper, and approved the final manuscript.
- 258 Chucks Anachebe authored drafts of the paper and approved the final manuscript.
- Dr. Brian Piper authored drafts of the paper, analyzed data, and approved the final manuscript.


261 Conflicts of Interest

- 262 The authors do not report any conflicts of interest.
- 263 Acknowledgments
- We would like to thank Elizabeth Kuchinski, MPH and Dan Kaufman, MBS at Geisinger
- 265 Commonwealth School of Medicine for their guidance and feedback throughout this 266 study.
- 267
- 268 **References**

- Andreae, M. H., Rhodes, E., Bourgoise, T., Carter, G. M., White, R. S., Indyk, D., ... &
- 270 Rhodes, R. (2016). An ethical exploration of barriers to research on controlled
 271 drugs. *The American Journal of Bioethics*, *16*(4), 36-47.
- ARCOS Retail Drug Summary Report 2011 Reporting Period. (n.d.). Retrieved
 January 27, 2021, from
- https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/2011/index.html
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical
 cannabis laws and opioid analgesic overdose mortality in the United States, 19992010. JAMA internal medicine, 174(10), 1668-1673.
- Blake, E. A., Ross, M., Ihenacho, U., Figueroa, L., Silverstein, E., Flink, D., ... & Roman,
 L. (2019). Non-prescription cannabis use for symptom management amongst
 women with gynecologic malignancies. *Gynecologic oncology reports*, *30*, 100497.
- Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated
 with decreased opiate medication use in a retrospective cross-sectional survey of
 patients with chronic pain. *The Journal of Pain*, *17*(6), 739-744.
- Bohnert, A. S., Guy Jr, G. P., & Losby, J. L. (2018). Opioid prescribing in the United
 States before and after the Centers for Disease Control and Prevention's 2016
 opioid guideline. *Annals of internal medicine*, *169*(6), 367-375.
- Bradford, A. C., & Bradford, W. D. (2016). Medical marijuana laws reduce prescription medication use in Medicare Part D. *Health Affairs*, *35*(7), 1230-1236.
- Cabrera, F. F., Gamarra, E. R., Garcia, T. E., Littlejohn, A. D., Chinga, P. A., Pinentel Morillo, L. D., ... & Piper, B. J. (2019). Opioid distribution trends (2006–2017) in the
 US Territories. *PeerJ*, 7, e6272.
- NIDA. 2020, April 3. California: Opioid-Involved Deaths and Related Harms. Retrieved
 from https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by state/california-opioid-involved-deaths-related-harms on 2021, February 20
- NIDA. 2020, April 3. Texas: Opioid-Involved Deaths and Related Harms. Retrieved from
 https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/texas opioid-involved-deaths-related-harms on 2021, February 20
- Friede, A., Rosen, D. H., & Reid, J. A. (1994). CDC WONDER: a cooperative
 processing architecture for public health. *Journal of the American Medical Informatics Association*, 1(4), 303-312.
- Huey, J., & Apollonio, D. E. (2019). Review of Tobacco Policies on University of California Campuses. *Californian Journal of Health Promotion*, *17*(1), 24-30.
- Ighodaro, E. O., McCall, K. L., Chung, D. Y., Nichols, S. D., & Piper, B. J. (2019).
 Dynamic changes in prescription opioids from 2006 to 2017 in Texas. *PeerJ*, 7, e8108.
- Jones, G. H., Bruera, E., Abdi, S., & Kantarjian, H. M. (2019). The opioid epidemic in
 the United States—overview, origins, and potential solutions. *Obstetrical & Gynecological Survey*, *74*(5), 278-279.
- Kaufman, D. E., Nihal, A. M., Leppo, J. D., Staples, K. M., McCall, K. L., & Piper, B. J.
 (2021). Opioid mortality following medical marijuana implementation in the United
 States. Pharmacopsychiatry. 54: 1-5. In press.
- Kienzl, M., Storr, M., & Schicho, R. (2020). Cannabinoids and opioids in the treatment of

- inflammatory bowel diseases. *Clinical and translational gastroenterology*, *11*(1).
- Lee, G., Grovey, B., Furnish, T., & Wallace, M. (2018). Medical cannabis for neuropathic pain. *Current pain and headache reports*, 22(1), 1-12.
- List Of Opioids From Strongest To Weakest Addiction Resource. (n.d.). Retrieved
 January 27, 2021, from https://www.addictionresource.net/blog/opioids-strongest weakest/
- McGinty, E. E., Barry, C. L., Stone, E. M., Niederdeppe, J., Kennedy-Hendricks, A.,
 Linden, S., & Sherman, S. G. (2018). Public support for safe consumption sites and
 syringe services programs to combat the opioid epidemic. *Preventive medicine*, *111*, 73-77.
- Piper, B. J., Shah, D. T., Simoyan, O. M., McCall, K. L., & Nichols, S. D. (2018). Trends
 in medical use of opioids in the US, 2006–2016. *American journal of preventive medicine*, 54(5), 652-660.
- Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V. (2019). Safety and
 efficacy of medical cannabis in fibromyalgia. *Journal of clinical medicine*, 8(6), 807.
- Shover, C. L., Davis, C. S., Gordon, S. C., & Humphreys, K. (2019). Association
 between medical cannabis laws and opioid overdose mortality has reversed over
 time. *Proceedings of the National Academy of Sciences*, *116*(26), 12624-12626.
- Sparber, S., Jones, A. (2020). Texas' medical marijuana program is one of the most
 restrictive in the country. Advocates hope the Legislature will change that. Texas
 Tribune. Accessed 2/20/2021 at: https://www.texastribune.org/2021/01/04/texas medical-marijuana-2021/
- U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center. (n.d.).
 Retrieved January 27, 2021, from https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html
- Ware, M. A., Wang, T., Shapiro, S., Collet, J. P., Boulanger, A., Esdaile, J. M., ... &
 O'Connell, C. (2015). Cannabis for the management of pain: Assessment of safety
 study (COMPASS). *The Journal of Pain*, *16*(12), 1233-1242.
- 341
- 342
- 343
- 344
- 544
- 345





348

- Figure 1. Total opioid distribution in California and Texas in Morphine Mg Equivalents 349
- (MME) by zip code as reported to the Drug Enforcement Administrations Automation of 350 Reports and Consolidated Ordering System in 2014 (A) and 2018 (B). Percent change 351
- from 2014 to 2018 (C). 352





Figure 2. Opioid distribution (+SEM) per zip code as reported by the Drug Enforcement 354 Administration's Automation of Reports and Consolidated Orders System. Morphine Mg 355 Equivalent: MME. * p < .05 versus 2014. 356



357

Figure 3. Per capita distribution of selected opioids from 2014 to 2018 as reported to 358

the Drug Enforcement Administration's Automation of Reports and Consolidated Orders 359

System in California (A) and Texas (B). The percent change from 2014 to 2018 is 360 361 shown in the key.





Figure 4. Opioid overdose rates as reported by the CDC's Wide Ranging Online Data for Epidemiologic Research (WONDER) from 1999 to 2019 in California (A) and Texas 362


363

(B). The percent change from 1999 to 2019 is listed in the key. 364



365

- **Figure S1.** Cumulative change in opioid distribution as reported to the Drug
- 367 Enforcement Administration's Automation of Reports and Consolidated Orders System 368 in California and Texas from 2014 to 2018.



- 370 **Figure S2.** Opioid composition as reported to the Drug Enforcement Administration's
- Automation of Reports and Consolidated Orders System per state (California : CA,
- 372 Texas: TX) in 2014 (top) and 2018 (bottom).